$CVI

CVR Energy (NYSE:CVI) Stock Price Expected to Rise, Mizuho Analyst Says

Mizuho raised its CVR Energy (NYSE:CVI) price target to $35 from $32 and kept an “underperform” rating, implying about 10.27% upside from the prior close, according to Benzinga. Other firms issued mixed ratings. CVI shares opened at $31.74. In its Apr. 29 quarter, CVR reported EPS of -$1.24 and revenue of $1.98B.

Original reporting
Published May 27, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CVR Energy (NYSE:CVI) Stock Price Expected to Rise, Mizuho Analyst Says — source image
Decision brief

The 30-second read

$CVIBullishMed
01

Why it matters

The primary tradable input is the Mizuho target increase, but the broader sell/underperform backdrop and the recent earnings miss raise the risk of a muted rally.

02

Market read

Analyst target lift may support a short-term technical/positioning bounce, but consensus remains heavily negative and fundamentals recently disappointed.

03

What to watch

The article highlights negative net margin and negative ROE from the last quarter; without margin improvement, price-target upside may not translate into earnings revisions.

Relevance 8/10Timing: Immediate (analyst note published Wednesday) with potential follow-through over subsequent sessions as traders reprice targets.

Background

The piece summarizes analyst rating/target changes for CVR Energy and reiterates its latest quarterly results (EPS miss, revenue beat) plus current technical/valuation snapshot.

Company-level read

Ticker impact

$CVIBullishMedium confidence
Context

Mizuho lifted its CVR Energy price objective from $32 to $35 and kept an “underperform” stance, implying ~10% upside versus the prior close.

Expected impact

Near-term bounce possible toward the new target, but upside may be capped unless fundamentals re-accelerate after the April earnings miss.

Evidence & confidence

The article is driven by analyst target changes rather than new company fundamentals; however, it references a recent EPS miss and ongoing sell/underperform consensus, which can limit follow-through.

Market effects

Reinforces that downstream refiners can see target dispersion even after earnings misses, keeping attention on refining margins and earnings quality.

Limited; CVR is US-focused and the catalyst is analyst-driven rather than a regional macro shock.

Low; no direct global event is cited beyond general oil-and-gas equity sentiment.

Counterpoint

Despite the raised target, multiple firms still rate CVI Sell/underperform, suggesting the market may discount the target increase as insufficient to change the risk profile.

Key entities

  • CVR Energy

    Independent downstream energy company; subject of the analyst price-target lift and the recent earnings results referenced in the article.

  • Mizuho

    Raised CVI price objective from $32 to $35 while maintaining an underperform rating.

Related articles

$CVIMed

CVR Energy Reports Second Quarter 2026 Results

CVR ENERGY INC (CVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CVR Energy Reports Second Quarter 2026 Results • Second quarter 2026 net loss attributable to CVR Energy stockholders of $3 million; Adjusted EBITDA of $209 million • Declared cash dividend of 10 cents for the second quarter 2026 • CVR Partners, LP (“CVR Partners”) a

$GMABMedAI 9/10

Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Launch Backlog Tops 100 After Synspective Deal

Rocket Lab's (RKLB) launch backlog exceeded 100 missions after a 20-launch deal with Synspective. The company's backlog grew from 70+ to over 100 missions in five months. Synspective is now Rocket Lab's largest customer with 47 launches. Rocket Lab's financial backlog was $2.2bn in Q1 2026, up 20.2% from the prior quarter. The company's revenue has doubled over two years, but it remains unprofitable.